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Prescription Monitoring Program Update
As of July 11, 2013, 4,155 prescribers have registered to use 
the prescription monitoring program (an increase of 24% from 
one year ago) and 1,885 pharmacists have registered to use the 
program (an increase of 44% from one year ago). Between 
January 1, 2012 and December 31, 2012, a total of 112,437 
requests for data were submitted to the program. Between 
January 1, 2013 and June 30, 2013, a total of 79,111 requests 
were submitted. If this trend continues during the remainder 
of 2013, the number of requests in 2013 will increase by 41% 
over 2012. The program has registered 252 practitioner agents 
and 39 pharmacist agents as of July 11, 2013. The program is 
continuing to reduce the incidence of patients who utilize mul-
tiple pharmacies and multiple prescribers to obtain controlled 
substances in Iowa. 
Iowa Board of Pharmacy Licensing and 
Registration Statistics – Summer 2013
Iowa-licensed pharmacists: 5,898 (3,462 residing in Iowa)
Registered, nationally certified pharmacy technicians: 4,306
Registered, uncertified pharmacy technicians (including 
trainees): 1,201
Total technicians: 5,507
Registered pharmacy support persons: 1,404
Pharmacist interns: 1,572
Total support staff: 8,483
Iowa pharmacies: 939
Nonresident (out-of-state) pharmacies: 617
Controlled Substances Act registrants (includes pharmacies):
16,509
Wholesalers (in state): 202
Wholesalers (nonresident): 1,294
Wholesalers (total): 1,496
Pharmacy Benefit Managers 
Today, more than 210 million Americans nationwide receive 
drug benefits administered by pharmacy benefit managers 
(PBMs). It is estimated that there are fewer than 100 major 
PBM companies in the United States. The Iowa Board of 
Pharmacy office routinely receives numerous questions about 
the activities of PBMs. In Iowa, PBMs are regulated by the 
Iowa Department of Commerce, Insurance Division. Current 
law resides in Iowa Code, Chapter 510B and administrative 
rules are located in 191 Iowa Administrative Code, Chapter 
59. The law and rules have been in effect since 2007-2008. A 
copy of Iowa law and rules for PBMs is included as an insert 
to this issue of the Newsletter. PBMs are required to obtain 
the approval of the prescribing practitioner prior to request-
ing any drug substitution under Iowa Code §510B.6. A PBM 
may not substitute an equivalent prescription drug contrary 
to a prescription drug order that prohibits a substitution. 
PBMs are required to develop an internal system to record 
and report complaints. These requirements are contained in 
191 I.A.C. 59.5(1). The Iowa Insurance Division has drafted 
some specific instructions for pharmacists who wish to file a 
complaint against a PBM, which are available online at www 
.iid.state.ia.us/file_a_complaint. PBMs are required to submit 
a summary of all complaints filed against them with the Iowa 
commissioner of insurance on a quarterly basis. Forty-eight 
PBMs are listed in the online directory of the Pharmacy Benefit 
Management Institute at www.pbmi.com/pbmdir.asp. None of 
these companies are located in Iowa. In 2012, the five largest 
PBMs in the US were Express Scripts of St Louis, MO; CVS 
Caremark of Scottsdale, AZ; Prime Therapeutics of Eagan, 
MN; OptumRx of Irvine, CA; and Catamaran of Lisle, IL. 
Update on Epilepsy Medications
A committee of the Board met with representatives of the 
Iowa Epilepsy Treatment & Education Task Force on June 
12, 2013. The discussion focused on the proper handling of 
prescriptions for brand-name products, generic products, 
and branded generic products. The advantage of having the 
patient’s diagnosis on the prescription was also discussed. All 
parties agreed on the following course of action: (1) clarify, 
in Board rules, the difference between generics and branded 
generics vis-à-vis Iowa’s law for drug product selection; (2) 
clarify the proper method for dispensing products from more 
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In a recent study funded by a grant from Agency for Healthcare Re-
search and Quality, ISMP evaluated the use of a combined checklist and 
patient information leaflet used during mandatory counseling sessions for 
consumers who pick up a filled prescription for 11 targeted medications:
All 11 medications are on ISMP’s list of high-alert medications dis-
pensed from community pharmacies. Errors with high-alert medications 
may not be more frequent than errors with other medications; however, 
the consequences of errors with high-alert medications are often harmful. 
These 11 medications are also among the top 200 drugs dispensed in 
the United States, and many are used to treat chronic conditions, thus 
increasing the potential impact on public safety. 
The medications were flagged in some manner to identify mandatory 
counseling opportunities. When a patient or patient representative picked 
up a flagged prescription, a pharmacist conducted a short counseling 
session (one to three minutes) that included the exchange of several 
key points on the checklist. At the end of the counseling session, the 
pharmacist provided the leaflet to the patient, along with a survey to 
complete and send back to ISMP. 
Counseling sessions for these drugs were conducted for a consecu-
tive period of four weeks, during which time, one trained ISMP staff 
member observed the counseling sessions for one day (six hours) to 
collect information on factors that facilitate or inhibit the counseling 
sessions. At the end of the four-week period of mandatory counseling, 
pharmacists at participating pharmacies were asked to complete a short 
mail-in survey regarding their perceived value of the process. 
Results of the study showed that these consumer leaflets offer impor-
tant safety tips for taking medication safely. Each leaflet begins with, 
“High-alert medicines have been proven to be safe and effective. But 
these medicines can cause serious injury if a mistake happens while tak-
ing them. This means that it is vitally important for you to know about 
this medicine and take it exactly as intended.”
ISMP tested the readability, usability, and perceived value of the 
leaflets. Ninety-four percent of patients felt the leaflets provided great 
information or good information to know. Ninety-seven percent felt the 
information in the leaflets was provided in a way they could understand. 
Eighty-two percent of patients taking the drug for the first time and 48% 
of patients who had previously taken the medication reported learning 
something new. Overall, 85% of the patients felt they were less likely to 
make a mistake with the medication because they had read the leaflet.
The leaflets are available for download and can be reproduced for free 
distribution to consumers at www.ismp.org/AHRQ/default.asp?link=ha.
Generic Drug Substitution Requires Pharmacist 
Attention to State Laws and Regulations
While 40 years ago, most states forbade prescription drug substitu-
tion, almost all states now have drug product selection laws that allow, 
encourage, or mandate pharmacists to substitute generics for brand-name 
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Pharmacists Likely to Recommend OTC 
Medications, CHPA Reports
Patients most often seek a pharmacist’s advice on treating coughs, 
headaches, migraines, and allergies, and 98% of pharmacists recommend 
or have no reservations recommending over-the-counter (OTC) prod-
ucts to treat such ailments, according to a recent survey. The Consumer 
Healthcare Products Association’s (CHPA) report, “Understanding 
Trust in OTC Medicines: Consumers and Healthcare Provider Perspec-
tives,” presents the results of the survey, which was developed to better 
understand what drives consumer and health care provider trust in OTC 
products. The survey, developed and conducted by Nielsen and IMS, 
included over 1,100 consumer respondents, and over 500 health care 
provider respondents, composed of pharmacists, pediatricians, nurse 
practitioners, and primary care providers.
Pharmacists surveyed reported that they were more likely to recom-
mend OTC products that demonstrated successful patient outcomes 
and consistent outcomes, and products known to be as efficacious as a 
prescription drug, and those containing ingredients known to be safe. 
The survey also asked health care providers whether they recom-
mended OTC products without, before, or in conjunction with rec-
ommending prescription drugs for certain symptoms. A majority of 
pharmacists surveyed, over 60%, recommend OTC medications to treat 
stomach symptoms and pain, without recommending a prescription 
treatment, and over 70% recommended OTC allergy, sinus, and flu 
medications without advising that a prescription drug is needed. 
CHPA notes that with the expansion of patient self-care, OTC 
products will play an increasingly important role in health care. The 
potential for more prescription products to become OTC products in 
the new paradigm under consideration by Food and Drug Administra-
tion (FDA) could further impact this trend. As consumers are becoming 
more empowered in making health care decisions, they are also relying 
more on their pharmacist for medication advice. In fact, Nielsen and IMS 
findings show that multigenerational households, Hispanic households, 
and households who care for an adult outside of their home place a high 
value on pharmacist recommendations regarding selecting appropriate 
OTC medications, notes CHPA. 
The full CHPA White Paper is available at www.yourhealthathand 
.org/images/uploads/OTC_Trust_Survey_White_Paper.pdf. 
ISMP Study on Targeted Mandatory Patient 
Counseling 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP is 
an independent nonprofit agency that analyzes 
medication errors, near misses, and potentially hazardous conditions 
as reported by pharmacists and other practitioners. ISMP then 
makes appropriate contacts with companies and regulators, 
gathers expert opinion about prevention measures, and publishes 
its recommendations. To read about the risk reduction strategies 
that you can put into practice today, subscribe to ISMP Medication 
Safety Alert!® Community/Ambulatory Care Edition by visiting www 
.ismp.org. ISMP is a federally certified patient safety organization, 
providing legal protection and confidentiality for submitted patient 
safety data and error reports. ISMP is also an FDA MedWatch partner. 
Call 1-800/FAIL-SAF(E) to report medication errors to the ISMP 
Medication Errors Reporting Program or report online at www.ismp 
.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, PA 19044. 
Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
 ♦ Opioid-containing analgesics 
◊	 fentanyl patches
◊	 hydrocodone with  
acetaminophen
◊	 oxycodone with  
acetaminophen
 ♦ Anticoagulants
◊	 warfarin
◊	 enoxaparin
 ♦ Antidiabetic drugs (insulin 
analogs)
◊	 Humalog® (insulin lispro)
◊	 NovoLog® (insulin aspart)
◊	 Levemir® (insulin detemir)
◊	 Lantus® (insulin glargine)
◊	 Apidra® (insulin glulisine)
 ♦ Antineoplastic drug (non-
oncologic use) 
◊	 methotrexate
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drugs. These laws vary widely from state to state and pharmacists are 
therefore encouraged to review their state’s substitution laws to ensure 
that they understand and comply with the state’s requirements.
FDA’s Approved Drug Products With Therapeutic Equivalence 
Evaluations publication, commonly known as the Orange Book, is 
generally considered the primary source for identifying suitable generic 
alternatives for a brand-name drug, and while not mandated by FDA 
regulations, the majority of states use the Orange Book’s determinations 
of therapeutic equivalence to legally guide pharmacists in substituting 
generics.
State laws on generic substitution vary widely. A few states, such as 
Kentucky or Minnesota, follow a “negative formulary” approach, in 
which substitution is permitted for all drugs except those that appear on 
a particular list. Other states, including Massachusetts and Wisconsin, 
use a “positive formulary” approach, in which substitution is limited to 
the drugs on a particular list. 
States also differ as to whether their substitution laws are permis-
sive, thereby allowing a pharmacist to substitute a generic version of 
a brand-name drug, provided all prescription requirements are met, or 
mandatory, thereby requiring substitution. Prescription requirements 
may include such factors as the availability of a cheaper, therapeutically 
equivalent drug, the prescriber’s specification that a brand-name drug be 
dispensed, or requiring the patient’s or prescriber’s consent. As reported 
in the 2013 NABP Survey of Pharmacy Law, 14 boards of pharmacy 
indicate that generic substitution falls into the “mandatory” category, 
while 38 boards indicate that their substitution laws are “permissive.” 
Oklahoma law states that “[I]t is unlawful for a pharmacist to substitute 
without the authority of the prescriber or purchaser.”
Other regulatory variations include states specifying the acceptable 
means for the prescriber to designate that substitution is not authorized, 
and states requiring patient consent prior to substitution. 
The full article on this subject, which also reviews considerations 
regarding the accuracy of therapeutic equivalent determinations, is avail-
able in the June-July 2013 NABP Newsletter, which may be accessed in 
the Publications section of www.nabp.net.
NHF Provides Standards of Care for Pharmacies 
Serving Hemophilia Patients
For pharmacies that offer blood-clotting medications, organizations 
such as the National Hemophilia Foundation (NHF) emphasize the 
importance of being able to meet the specialized needs of their patients 
with bleeding disorders. 
NHF’s Medical and Scientific Advisory Council (MASAC) issued a 
standards-of-care recommendation in 2008 to assist pharmacies provid-
ing clotting factor concentrates for home use to patients with bleeding 
disorders. MASAC’s guidelines are intended to be minimum standards 
of care and are divided into six areas:
As a brief overview of the MASAC guidelines, pharmacists wishing 
to meet the standards should: 
1. Have a basic knowledge of bleeding disorders and experience with 
and knowledge of the full range of clotting factor concentrates, 
ancillary supplies, and hazardous waste disposal. 
Pharmacies wishing to meet MASAC standards:
2. Should be able to provide a full range of available concentrates in 
all available assays and vial sizes, along with all necessary ancillary 
supplies, and hazardous waste disposal assistance as well as access 
to nursing services.
3. Should support reliable access to clotting factor for appropriate 
home treatment, by filling prescription orders within 48 hours, in 
the quantities prescribed, with expiration dates commensurate with 
the individual patient’s needs. 
4. Should be reliably open during regular business hours; provide 24-
hour emergency access; and have an emergency action plan that 
allows patients to receive factor within 12 hours “in case of emergent 
need,” with a goal of three hours “where logistically possible.”
5. Should deliver products to the patient’s desired location, meeting 
federal medication shipping standards, and providing an emergency 
number for patients to call in case of a problem with a delivery. 
6. Should maintain patients’ treatment prescription information along 
with maintaining records in compliance with state and federal 
requirements and be able to track the clotting factor products from 
manufacturer to patient, and participate in a recall information 
system.
The full article on this topic is available in the June-July 2013 NABP 
Newsletter, accessible in the Publications section of www.nabp.net. 
NABP notes that each state needs to review the standards recommended 
by MASAC to determine whether they coincide with existing state board 
of pharmacy requirements. NABP recognizes the unique patient needs 
of hemophiliacs, but also the responsibility of state boards of pharmacy 
to set required standards for medication dispensing and use. NABP is 
working with NHF to help the boards of pharmacy gain a better under-
standing of the medication needs of patients to help achieve uniformity 
in related regulations. 
NABPLAW Online Now Includes Guam, Puerto 
Rico, and the Virgin Islands 
The complete pharmacy acts and regulations of Guam, Puerto Rico, 
and the Virgin Islands are now included in NABPLAW® Online, the 
comprehensive national data bank of state pharmacy laws and regulations 
provided by NABP. NABPLAW Online’s powerful search capabili-
ties allow users to research subjects one state at a time or across all 50 
states and included jurisdictions. More information about NABPLAW 
Online and a link to the online subscription order form are available in 
the Programs section of the NABP Web site at www.nabp.net/programs/
member-services/nabplaw/.
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
Continuing pharmacy education (CPE) providers who are accredited 
by the Accreditation Council for Pharmacy Education (ACPE) 
have integrated CPE Monitor® into their systems and are requiring 
pharmacists and pharmacy technicians to provide an NABP e-Profile ID 
number and date of birth (MMDD) in order to process ACPE-accredited 
CPE credit.
Visit www.MyCPEmonitor.net to set up your NABP e-Profile and 
register for CPE Monitor and avoid possible delays in your CPE 
reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056
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than one company in a single prescription due to a drug short-
age or other extenuating circumstance (ie, mixing two different 
generic products in the same prescription vial); and (3) educate 
pharmacists on the need to notify prescribers whenever a 
change is made in the dispensing of a patient’s epilepsy medi-
cations. The Board will publish proposed changes in rules as 
soon as they are available and will continue to work with the 
members of the Epilepsy Task Force to resolve dispensing is-
sues and ensure patient safety. A recent study in the Journal 
of the American Medical Association Internal Medicine has 
concluded that “changes in pill color significantly increase 
the odds of nonpersistence; this may have important clinical 
implications. Our study supports a reconsideration of current 
regulatory policy that permits wide variation in the appearance 
of bioequivalent drugs.”  
Source: “Variations in Pill Appearance of Antiepileptic Drugs and 
the Risk of Nonadherence,” JAMA Intern Med. 2013; 173(3): 202-
208. Background: “Generic prescription drugs are bioequivalent 
to brand-name versions but may not have consistent color or shape, 
which can cause confusion and lead to interruptions in medication 
use. This study sought to determine whether switching among 
different-appearing antiepileptic drugs (AEDs) is associated with 
increased rates of medication nonpersistence, which can have serious 
medical, financial and social consequences.”
50-Year Pharmacists
The Board congratulates the following 25 Iowa pharma-
cists who were originally licensed in 1963, have continuously 
maintained their Iowa pharmacist license, and have devoted a 
half-century of service to the public and the profession: Thomas 
A. Ayres, Norman, OK; James L. Aswegan, Carlsbad, CA; 
Richard L. Abrahamson, Edmond, OK; Byrl D. Blackmer, 
Ankeny, IA; Monte R. Baugher, West Des Moines, IA; Lyman 
A. Berge, Peoria, IL; Robbin R. Burns, Waterloo, IA; Robert 
E. Bellinger, Fort Dodge, IA; Clarke H. Cordes, Lakeland, 
FL; David C. Dyball, Meckling, SD; James G. Dickerson, 
Sr, Gretna, NE; William M. Dimig, Atlantic, IA; Thomas B. 
Dodds, Dakota Dunes, SD; Gus T. Erickson, Clear Lake, IA; 
Thomas H. Hofer, Kalona, IA; Larry L. Hurst, Runnells, IA; 
Lamoine O. Gearhart, Ontario, OR; Shelva J. King, East Moine, 
IL; Kenneth R. Moorman, Atlantic, IA; Cornelius Maris, Jr, 
Spirit Lake, IA; Robert G. Nieland, Eldridge, IA; Richard W. 
Severson, Martinez, GA; Thomas J. Sullivan, Keosauqua, IA; 
Paul E. Twedt, Ames, IA; and Judith A. Woolums, Ottumwa, 
IA.
Next Board Meeting
The Board plans to hold its next meeting on November 5-6, 
2013. Administrative hearings and a closed session will be held 
at the Board office in Des Moines, IA, on November 5. The 
Board plans to meet in open session in Council Bluffs, IA, on 
November 6. Please contact the Board office at 515/281-5944 
to confirm times and locations.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the ef-
fective regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices. 
Iowa Code §155A.2(1).
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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IOWA CODE CHAPTER 510B
REGULATION OF PHARMACY BENEFITS MANAGERS
510B.1 Definitions.
510B.2 Certification as a third-party administrator required.
510B.3 Enforcement — rules.
510B.4 Performance of duties — good faith — conflict of interest.
510B.5 Contacting covered individual — requirements.
510B.6 Dispensing of substitute prescription drug for prescribed drug.
510B.7 Duties to pharmacy network providers.
510B.1 Definitions.
As used in this chapter, unless the context otherwise requires:
1. “Commissioner” means the commissioner of insurance.
2. “Covered entity” means a nonprofit hospital or medical services corporation, health
insurer, health benefit plan, or health maintenance organization; a health program
administered by a department or the state in the capacity of provider of health coverage;
or an employer, labor union, or other group of persons organized in the state that provides
health coverage. “Covered entity” does not include a self-funded health coverage plan
that is exempt from state regulation pursuant to the federal Employee Retirement Income
Security Act of 1974 (ERISA), as codified at 29 U.S.C. § 1001 et seq.; a plan issued for health
coverage for federal employees; or a health plan that provides coverage only for accidental
injury, specified disease, hospital indemnity, Medicare supplemental, disability income, or
long-term care, or other limited benefit health insurance policy or contract.
3. “Covered individual” means a member, participant, enrollee, contract holder,
policyholder, or beneficiary of a covered entity who is provided health coverage by the
covered entity, and includes a dependent or other person provided health coverage through
a policy, contract, or plan for a covered individual.
4. “Generic drug” means a chemically equivalent copy of a brand-name drug with an
expired patent.
5. “Labeler” means a person that receives prescription drugs from a manufacturer or
wholesaler and repackages those drugs for later retail sale and that has a labeler code from
the federal food and drug administration pursuant to 21 C.F.R. § 207.20.
6. “Pharmacy” means pharmacy as defined in section 155A.3.
7. “Pharmacy benefits management” means the administration or management of
prescription drug benefits provided by a covered entity under the terms and conditions of
the contract between the pharmacy benefits manager and the covered entity.
8. “Pharmacy benefits manager” means a person who performs pharmacy benefits
management services. “Pharmacy benefits manager” includes a person acting on behalf of a
pharmacy benefits manager in a contractual or employment relationship in the performance
of pharmacy benefits management services for a covered entity. “Pharmacy benefits
manager” does not include a health insurer licensed in the state if the health insurer or
its subsidiary is providing pharmacy benefits management services exclusively to its own
insureds, or a public self-funded pool or a private single employer self-funded plan that
provides such benefits or services directly to its beneficiaries.
9. “Prescription drug” means prescription drug as defined in section 155A.3.
10. “Prescription drug order” means prescription drug order as defined in section 155A.3.
510B.2 Certification as a third-party administrator required.
A pharmacy benefits manager doing business in this state shall obtain a certificate as a
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third-party administrator under chapter 510, and the provisions relating to a third-party
administrator pursuant to chapter 510 shall apply to a pharmacy benefits manager.
510B.3 Enforcement — rules.
1. The commissioner shall enforce the provisions of this chapter.
2. The commissioner shall adopt rules pursuant to chapter 17A to administer this chapter
including rules relating to all of the following:
a. Timely payment of pharmacy claims.
b. A process for adjudication of complaints and settlement of disputes between a
pharmacy benefits manager and a licensed pharmacy related to pharmacy auditing practices,
termination of pharmacy agreements, and timely payment of pharmacy claims.
510B.4 Performance of duties — good faith — conflict of interest.
1. A pharmacy benefits manager shall perform the pharmacy benefits manager’s duties
exercising good faith and fair dealing in the performance of its contractual obligations toward
the covered entity.
2. A pharmacy benefits manager shall notify the covered entity in writing of any activity,
policy, practice ownership interest, or affiliation of the pharmacy benefits manager that
presents any conflict of interest.
510B.5 Contacting covered individual — requirements.
A pharmacy benefits manager, unless authorized pursuant to the terms of its contract
with a covered entity, shall not contact any covered individual without the express written
permission of the covered entity.
510B.6 Dispensing of substitute prescription drug for prescribed drug.
1. The following provisions shall apply when a pharmacy benefits manager requests the
dispensing of a substitute prescription drug for a prescribed drug to a covered individual:
a. The pharmacy benefits manager may request the substitution of a lower priced generic
and therapeutically equivalent drug for a higher priced prescribed drug.
b. If the substitute drug’s net cost to the covered individual or covered entity exceeds
the cost of the prescribed drug, the substitution shall be made only for medical reasons that
benefit the covered individual.
2. A pharmacy benefits manager shall obtain the approval of the prescribing practitioner
prior to requesting any substitution under this section.
3. A pharmacy benefits manager shall not substitute an equivalent prescription drug
contrary to a prescription drug order that prohibits a substitution.
510B.7 Duties to pharmacy network providers.
1. A pharmacy benefits manager shall not mandate basic recordkeeping that is more
stringent than that required by state or federal law or regulation.
2. If a pharmacy benefits manager receives notice from a covered entity of termination of
the covered entity’s contract, the pharmacy benefits manager shall notify, within ten working
days of the notice, all pharmacy network providers of the effective date of the termination.
3. Within three business days of a price increase notification by a manufacturer or
supplier, a pharmacy benefits manager shall adjust its payment to the pharmacy network
provider consistent with the price increase.
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191 IOWA ADMINISTRATIVE CODE (IAC) CHAPTER 59
PHARMACY BENEFITS MANAGERS
191—59.1 Purpose.
The purpose of this chapter is to administer the provisions of Iowa Code Supplement chapter 510B relating to the 
regulation of pharmacy benefits managers.
191—59.2 Definitions.
The terms defined in Iowa Code Supplement section 510B.1 shall have the same meaning for the purposes of 
this chapter. The definitions contained in 191—Chapter 58, “Third-Party Administrators,” and 191—Chapter 78, 
“Uniform Prescription Drug Information Card,” of the Iowa Administrative Code are incorporated by reference. 
As used in this chapter:
“Clean claim” means a claim which is received by any pharmacy benefits manager for adjudication and which 
requires no further information, adjustment or alteration by the pharmacist or pharmacies or the insured in order to 
be processed and paid by the pharmacy benefits manager. A claim is a clean claim if it has no defect or impropriety, 
including any lack of substantiating documentation, or no particular circumstance requiring special treatment that 
prevents timely payment from being made on the claim under this chapter. A clean claim includes a resubmitted 
claim with previously identified deficiencies corrected.
“Complaint” means a written communication expressing a grievance or an inquiry concerning a transaction 
between a pharmacy benefits manager and a pharmacy or pharmacist.
“Day” means a calendar day, unless otherwise defined or limited.
“Paid” means the day on which the check is mailed or the day on which the electronic payment is processed by 
the pharmacy benefits manager’s bank.
191—59.3 Timely payment of pharmacy claims.
59.3(1)
All benefits payable under a pharmacy benefits management plan shall be paid as soon as feasible but within 20 
days after receipt of a clean claim when the claim is submitted electronically and shall be paid within 30 days after 
receipt of a clean claim when the claim is submitted in paper format.
59.3(2)
Payments to the pharmacy or pharmacist for clean claims are considered to be overdue if not paid within 20 or 30 
days, whichever is applicable. If any clean claim is not timely paid, the pharmacy benefits manager must pay the 
pharmacy or pharmacist interest at the rate of 10 percent per annum commencing the day after any claim payment 
or portion thereof was due until the claim is finally settled or adjudicated in full.
59.3(3)
Existing contracts between clients and pharmacy benefits managers shall comply with the requirement that clean 
claims be paid within 20 or 30 days, whichever is applicable, when such contracts are renegotiated on or after 
January 1, 2009, but no later than December 31, 2009.
191—59.4 Study.
On or before December 31, 2009, the commissioner will examine the feasibility of requiring a 15-day payment 
schedule for electronically submitted claims. The examination shall include economic impact on pharmacy 
benefits managers, patients, and Iowa pharmacies.
191—59.5 Complaints.
59.5(1)
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Each pharmacy benefits manager shall develop an internal system to record and report complaints. This system 
shall include but not be limited to:
a. Complaints from the pharmacy indicating the reason for the complaint and factual documentation to support  
 the complaint;
b. Contact name, address and telephone number of the pharmacy benefits manager;
c. Contact name, address and telephone number of the pharmacy;
d. Prescription number;
e. Prescription reimbursement amount for disputed claim(s);
f. Disputed prescription claim payment date(s);
g. Plan benefits certificate.
59.5(2)
A summary of all complaints as outlined in subrule 59.5(1) received by the pharmacy benefits manager shall be 
submitted to the commissioner on a quarterly basis within 30 days after the calendar quarter has ended.
191—59.6 Auditing practices.
59.6(1)
An audit of the pharmacy records by a pharmacy benefits manager shall be conducted in accordance with the 
following:
a. The pharmacy benefits manager conducting the initial on-site audit must provide the pharmacy written notice 
at least one week prior to conducting any audit;
b. Any audit which involves clinical or professional judgment must be conducted by or in consultation with a 
pharmacist;
c. When a pharmacy benefits manager alleges an overpayment has been made to a pharmacy or pharmacist, the 
pharmacy benefits manager shall provide the pharmacy or pharmacist sufficient documentation to determine 
the specific claims included in the alleged overpayment;
d. A pharmacy may use the records of a hospital, physician or other authorized practitioner of the healing arts for 
drugs or medicinal supplies, written or transmitted by any means of communication, for purposes of validating 
the pharmacy record with respect to orders or refills of a legend or narcotic drug;
e. Each pharmacy shall be audited under the same standards and parameters as other similarly situated pharmacies 
audited by the pharmacy benefits manager;
f. The period covered by an audit may not exceed two years from the date on which the claim was submitted 
to or adjudicated by a managed care company, insurance company, third-party payor, or any pharmacy benefits 
manager that represents such companies, groups, or a department;
g. Unless otherwise consented to by the pharmacy, an audit may not be initiated or scheduled during the first seven 
calendar days of any month due to the high volume of prescriptions filled during that time;
h. The preliminary audit report must be delivered to the pharmacy within 120 days after conclusion of the audit. 
A final written audit report shall be received by the pharmacy within six months of the preliminary audit report 
or final appeal, whichever is later;
i. A pharmacy shall be allowed at least 30 days following receipt of the preliminary audit report in which to 
produce documentation to address any discrepancy found during an audit; and
j. The audit criteria set forth in this subrule shall apply only to audits of claims submitted for payment after 
December 31, 2008.
59.6(2)
Notwithstanding any other provision in this rule, the entity conducting the audit shall not use the accounting 
practice of extrapolation in calculating the recuperation of contractual penalties for audits.
59.6(3)
Recuperation of any disputed funds shall occur only after final disposition of the audit, including the appeals 
process as set forth in subrules 59.6(4) and 59.6(5).
59.6(4)
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Each pharmacy benefits manager conducting an audit shall establish an appeals process under which a pharmacy 
may appeal an unfavorable preliminary audit report to the pharmacy benefits manager. If, following the appeal, 
the pharmacy benefits manager finds that an unfavorable audit report or any portion thereof is unsubstantiated, 
the pharmacy benefits manager shall dismiss the audit report or said portion without the necessity of any further 
proceedings.
59.6(5)
If, following the final appeal, the pharmacy benefits manager finds that an unfavorable audit report or any portion 
thereof is found to be substantiated, the pharmacy benefits manager shall already have in place a process for an 
independent third-party review of the final audit findings. As part of the final appeal process of any final adverse 
decision, the pharmacy benefits manager shall notify the pharmacy in writing of its right to request an independent 
third-party review of the final audit findings and the process used to request such a review.
59.6(6)
Each pharmacy benefits manager conducting an audit shall, after completion of any review process, provide a 
copy of the final audit report to the plan sponsor.
59.6(7)
This rule shall not apply to any investigative audit which involves fraud, willful misrepresentation, abuse, or any 
other statutory provision which authorizes investigations relating to but not limited to insurance fraud.
191—59.7  Termination of pharmacy contracts.
59.7(1)
A pharmacy or pharmacist shall not be terminated from the network or penalized by a pharmacy benefits manager 
solely because of filing a complaint, grievance or appeal.
59.7(2)
A pharmacy or pharmacist shall not be terminated from the network or penalized by a pharmacy benefits manager 
due to any disagreement with the decision of the pharmacy benefits manager to deny or limit benefits to covered 
persons or due to any assistance provided to covered persons by the pharmacy or pharmacist in obtaining 
reconsideration of the decision of the pharmacy benefits manager.
59.7(3)
Termination of contracts between a pharmacy benefits manager and a pharmacy shall include a provision 
describing notification procedures for contract termination. The contract shall require no less than 60 days’ prior 
written notice by either party that wishes to terminate the contract.
59.7(4)
If the pharmacy benefits manager has evidence that the pharmacy or pharmacist has engaged in fraudulent conduct 
or poses a significant risk to patient care or safety, the pharmacy benefits manager may immediately suspend the 
pharmacy or pharmacist from further performance under the contract provided written notice of termination is 
provided to the pharmacy or pharmacist.
59.7(5)
Termination of a contract between a pharmacy benefits manager and a pharmacy or pharmacist or termination 
of a pharmacy or pharmacist from the network of the pharmacy benefits manager shall not release the pharmacy 
benefits manager from the obligation to make payments due to the pharmacy or pharmacist for services rendered 
before the contract of the pharmacy or pharmacist was terminated.
59.7(6)
Independent third-party review of termination decision. The pharmacy or pharmacist may request an independent 
third-party review of the final decision to terminate the contract between the pharmacy benefits manager and the 
pharmacy or pharmacist by filing with the pharmacy benefits manager a written request for an independent third-
party review of the decision. This written request must be filed with the pharmacy benefits manager within 30 
days of receipt of the final termination decision.
These rules are intended to implement Iowa Code chapters 17A and 514L and Iowa Code Supplement chapter 
510B.
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INSTRUCTIONS TO PHARMACISTS FOR FILING A COMPLAINT  
WITH THE IOWA INSURANCE DIVISION
1. Have you used your pharmacy benefits manager’s (PBM) complaint and appeal process to resolve 
your dispute? 
Iowa Code Chapter 510B requires all PBMs to develop an internal system for adjudication of complaints 
and settlement of disputes between a PBM and a licensed pharmacy. Before the Iowa Insurance Division 
(IID) may accept a complaint regarding a pharmacy issue, you must exhaust the complaint and appeals 
process provided by your PBM. If problems remain unresolved after participating in the appeal process, 
you may submit a complaint to the IID for assistance.
2. Network Policy Contract. If any of your Network Policy Contract provisions are central to your 
complaint, please provide the applicable contract language. 
3. Provide the following information regarding your complaint. 
•	 Your name, telephone number, and e-mail address
•	 Pharmacy name and address
•	 PBM’s full name
•	 Pharmacy Services Administration Organization (PSAO) (if applicable)
•	 Insurance company’s full name
•	 Prescription number
•	 Date of service
•	 Reason for complaint
o Each complaint should include one problem that involves one PBM. If there are multiple 
examples of a specific problem that involves one PBM, you may include all examples in 
one complaint. Please provide a thorough explanation of your problem and document it with 
examples.
o Provide examples for each problem and include documents that support your position. It is 
not necessary to provide a narrative for each individual example. 
Information the IID obtains in the course of an investigation is confidential. See Iowa Code, Section 505.8. 
If the insurance commissioner determines that it is necessary or appropriate in the public interest or for the 
protection of the public, the insurance commissioner may share information with other regulatory authorities 
or may publish information concerning violations of Iowa insurance law. If you feel the information you are 
providing to the IID should not be released under the discretionary authority of the insurance commissioner, 
clearly identify the documents or information and assert the privilege asserted. See Iowa Code, Section 22.7.
THE ROLE OF THE IOWA INSURANCE DIVISION IN REVIEWING PHARMACIST’S 
COMPLAINTS AGAINST PHARMACY BENEFIT MANAGERS
The IID regulates and supervises the business of PBMs in Iowa, pursuant to Iowa Code Chapter 510B and Iowa 
Administrative Code 191-59.
If this matter involves a dispute, we request you set forth your position including the relevant facts, contract 
language, and documents as described above that you feel would be helpful in our review. 
•	 By accepting your complaint, we have not made any assumptions about the validity of the complaint or 
the truth of your complaint.
•	 In handling this complaint, the IID does not represent any party to the dispute. We represent the state of 
Iowa in enforcing the relevant insurance laws and do not represent private parties.
•	 In making our decision, we rely on the information provided to us by the pharmacy, the PBM, the 
insurer, and other relevant parties to the complaint.
•	 In situations where it appears that a violation of Iowa insurance law has occurred, the Iowa insurance 
commissioner has the authority to issue administrative orders, hold administrative hearings, suspend or 
revoke TPA Certificate of Administration, and to impose monetary penalties.
The Iowa Insurance Division makes an independent evaluation of each matter received. We review 
PBM responses for the reasonableness of the actions taken, compliance with all applicable statutes and 
regulations, compliance with all contract provisions, and identification of appropriate actions taken to 
resolve this complaint. 
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